Dai Alper I, Aksoy Sefika N, Demiryürek Abdullah T
Department of Pediatrics, Faculty of Medicine, Division of Pediatric Neurology, University of Gaziantep, Gaziantep, Turkey
Department of Biochemistry, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey.
J Child Neurol. 2016 Feb;31(2):184-9. doi: 10.1177/0883073815587030. Epub 2015 May 21.
This retrospective study aimed to compare the therapeutic response, including side effects, for oral baclofen versus oral tizanidine therapy with adjuvant botulinum toxin type A in a group of 64 pediatric patients diagnosed with static encephalopathy and spastic equinus foot deformity. Following botulinum toxin A treatment, clinical improvement led to the gradual reduction of baclofen or tizanidine dosing to one-third of the former dose. Gross Motor Functional Measure and Caregiver Health Questionnaire scores were markedly elevated post-botulinum toxin A treatment, with scores for the tizanidine (Gross Motor Functional Measure: 74.45 ± 3.72; Caregiver Health Questionnaire: 72.43 ± 4.29) group significantly higher than for the baclofen group (Gross Motor Functional Measure: 68.23 ± 2.66; Caregiver Health Questionnaire: 67.53 ± 2.67, P < .001). These findings suggest that the combined use of botulinum toxin A and a low dose of tizanidine in treating children with cerebral palsy appears to be more effective and has fewer side effects versus baclofen with adjuvant botulinum toxin A.
这项回顾性研究旨在比较口服巴氯芬与口服替扎尼定联合辅助使用A型肉毒毒素治疗64例诊断为静态脑病和痉挛性马蹄足畸形的儿科患者的治疗反应，包括副作用。在A型肉毒毒素治疗后，临床改善导致巴氯芬或替扎尼定剂量逐渐减少至先前剂量的三分之一。在A型肉毒毒素治疗后，粗大运动功能测量和照顾者健康问卷得分显著提高，替扎尼定组得分（粗大运动功能测量：74.45±3.72；照顾者健康问卷：72.43±4.29）显著高于巴氯芬组（粗大运动功能测量：68.23±2.66；照顾者健康问卷：67.53±2.67，P<.001）。这些发现表明，与巴氯芬联合辅助使用A型肉毒毒素相比，A型肉毒毒素与低剂量替扎尼定联合用于治疗脑瘫患儿似乎更有效且副作用更少。
